Compatibility with new insulins opens up new market opportunities for Brighters Actisteer


Lighter AB (public) announced today that its diabetes management solution – Actiste® – is being evaluated and supplied with insulin cartridges from cartridge BIOTON SA (SciGen Pte. GmbH. – the exclusive distributor of BIOTON products, except Poland) with GENSULIN®GENSULIN® N (Scilin®N), GENSULIN® R (Scilin®R) and GENSULIN® M30 (Scilin®M30). Actiste® is currently only for use with insulin cartridges from Sanofi. This was a limiting factor in Brighter’s potential market reach because Sanofi Cartridges are not available in all markets.

“This is a great strategic step and a major milestone for Brighter. It will open additional markets with new revenue opportunities worldwide where Bioton / Scigen Insulin is available. After completing the internal development work, we assume that Actiste® will be ready for the market and for the end consumer as early as the second half of the year for use with the additional insulin, says Christer Trägerårdh, acting CEO of Brighter.

BIOTON SA is an innovative Polish biotechnology company that provides patients with safe and comprehensive solutions for diabetes care. Bioton is undoubtedly a leader in the Polish market and is one of the world’s eight leading commercial manufacturers of recombinant human insulin.

SciGen Pte. GmbH. is a high growth biopharmaceutical company focused on recombinant biotechnological products for human health. SciGens The focus is on the areas of endocrinology and oncology. The company’s portfolio consists of biosimilar products such as Rhuman growth hormone, Rhuman insulin and Rhuman GCSF. All SciGens Products have undergone significant clinical development

For more information, please contact:

Investor Relations
[email protected]

Certified consultant

Brighter’s certified advisor is Eminova Fondkommission AB, +46[[email protected][0)[email protected][[email protected][0)8-68421110 [email protected] wwweminovase

over Lighter AB (public)
Brighter is a health tech company Sweden with the vision of a world in which dealing with chronic diseases is no longer a struggle. We believe that a data-centric approach is key to more intelligent chronic disease care. Our daily care solutions were developed with the vision of facilitating the flow of real-life treatment data between patients with chronic illnesses, their relatives and their carers – with the aim of improving the quality of life, relieving the burden and opening up health systems new opportunities for data-driven research. Brighter is ISO 13485 certified. In 2019 the company won the Swecare Rising Stars Award. The company’s shares are listed on the Nasdaq First North Growth Market / BRIG.

This information is information that Lighter AB is obliged to publish according to the EU Market Abuse Regulation. The information has been submitted for publication to via the contact persons listed above 3:45 p.m. CET on June 7, 2021–publ-/r/compatibility-with-new-insulins-opens-up-new-market-opportunities-for-brighter-s-actiste-,c3362425

(c) Dissolution 2021. All rights reserved., Source Press releases – English

Source link

Leave A Reply

Your email address will not be published.